Medpace (NASDAQ:MEDP) Rating Increased to Outperform at Robert W. Baird

Robert W. Baird upgraded shares of Medpace (NASDAQ:MEDP) from a neutral rating to an outperform rating in a report issued on Tuesday, MarketBeat reports. Robert W. Baird currently has $564.00 price objective on the stock.

Several other brokerages also recently commented on MEDP. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. TD Cowen reaffirmed a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. Finally, Mizuho set a $660.00 price target on shares of Medpace in a research note on Friday, January 9th. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and an average target price of $486.82.

Medpace Trading Down 15.9%

Medpace stock opened at $446.05 on Tuesday. The firm has a market capitalization of $12.57 billion, a P/E ratio of 29.15, a PEG ratio of 1.78 and a beta of 1.42. The business has a 50-day moving average of $575.55 and a 200-day moving average of $539.56. Medpace has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 127.72%. The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts anticipate that Medpace will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. The trade was a 42.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This trade represents a 7.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 296,880 shares of company stock valued at $178,815,404 over the last three months. Insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

Hedge funds have recently made changes to their positions in the business. Quent Capital LLC bought a new position in shares of Medpace in the third quarter valued at about $25,000. Optiver Holding B.V. bought a new stake in shares of Medpace during the third quarter worth approximately $27,000. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace during the fourth quarter worth approximately $30,000. Finally, Elyxium Wealth LLC bought a new position in shares of Medpace during the fourth quarter worth approximately $30,000. 77.98% of the stock is owned by institutional investors and hedge funds.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q4 beat and upgraded FY2026 guidance — Medpace reported Q4 EPS of $4.67 and revenue of $708.5M (both above estimates) and set FY2026 EPS guidance of $16.68–$17.50 and revenue guidance ~$2.8–$2.9B, which exceeds consensus. This supports the company’s growth narrative and longer-term earnings outlook. Press Release
• Positive Sentiment: Analyst upgrade — Robert W. Baird upgraded MEDP from Neutral to Outperform and set a $564 price target, signaling increased analyst confidence that could attract buyers over time. The Fly
• Neutral Sentiment: Earnings call / disclosures — Management provided details in the Q4 2025 earnings call and slide deck; investors can review the full transcript and presentation to parse growth drivers, margin details, and backlog commentary. These documents underpin the beat but contain clarifying details that investors are digesting. Earnings Call Transcript
• Neutral Sentiment: Analyst commentary / valuation checks — Independent write-ups note that the quarter was strong but valuation is now richer (e.g., mid-30s P/E); some analysts see limited near-term upside absent backlog acceleration. These views help explain mixed reactions. Seeking Alpha Analysis
• Negative Sentiment: Backlog normalization and trial mix shifts — Management flagged backlog growth is normalizing and some metabolic trials are shifting timing, which reduces near-term revenue visibility and investor confidence in sustained double-digit growth. This was highlighted in coverage calling the guidance cautious on backlog dynamics. MSN: Backlog / Trial Shifts
• Negative Sentiment: Immediate market reaction — Despite the beat and raised guidance, shares sold off on the day as investors focused on the “key negative” of weaker backlog momentum and timing risk, leading to heavy volume and a notable intraday decline. Investing.com: Shares Tumble

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.